A phase II study on Mefatinib as first‐line treatment of patients with advanced non‐small‐cell lung cancer harboring uncommon EGFR mutations

• Pingli Wang,
• Liming Cao,
• Panwen Tian,
• Shengxiang Ren,
• Liyun Miao,
• Chengzhi Zhou,
• Yun Fan,
• Yuping Li,
• Dongqing Lv,
• Xin Zhao,
• Mei Yang,
• Chaonan Zhu,
• Bing Yu,
• June Xu,
• Yong Song,
• Kai Wang

Affiliations

Pingli Wang

Department of Respiratory and Critical Care Medicine The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang P. R. China

Liming Cao

Department of Respiratory Medicine Xiangya Hospital Central South University Changsha Hunan P. R. China

Panwen Tian

Department of Respiratory and Critical Care Medicine West China Hospital of Sichuan University Chengdu Sichuan P. R. China

Shengxiang Ren

Department of Medical Oncology Shanghai Pulmonary Hospital Shanghai P. R. China

Liyun Miao

Department of Respiratory Medicine The Affiliated Drum Tower Hospital of Nanjing University Medical School Nanjing Jiangsu P. R. China

Chengzhi Zhou

Department of Pulmonary and Critical Care Medicine The First Affiliated Hospital of Guangzhou Medical University Guangzhou Guangdong P. R. China

Yun Fan

Department of Medical Thoracic Oncology Cancer Hospital of University of Chinese Academy of Sciences Hangzhou Zhejiang P. R. China

Yuping Li

Department of Pulmonary and Critical Care Medicine The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang P. R. China

Dongqing Lv

Department of Respiratory Medicine Taizhou Hospital of Zhejiang Province Taizhou Zhejiang P. R. China

Xin Zhao

Department of Respiratory and Critical Care Medicine Jiangsu Province Hospital The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu P. R. China

Mei Yang

Huadong Global Development Center Hangzhou ZhongMei HuaDong Pharmaceutical Company Hangzhou Zhejiang P. R. China

Chaonan Zhu

Huadong Global Development Center Hangzhou ZhongMei HuaDong Pharmaceutical Company Hangzhou Zhejiang P. R. China

Bing Yu

Huadong Global Development Center Hangzhou ZhongMei HuaDong Pharmaceutical Company Hangzhou Zhejiang P. R. China

June Xu

Huadong Global Development Center Hangzhou ZhongMei HuaDong Pharmaceutical Company Hangzhou Zhejiang P. R. China

Yong Song

Department of Respiratory Medicine General Hospital of Eastern Theater Command Nanjing Jiangsu P. R. China

Kai Wang

Department of Respiratory and Critical Care Medicine The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang P. R. China